Pharma Supply Chain People Moves

All the latest appointments and promotions across the pharmaceutical supply chain sector...

June 2020:

Vaccine developer Novavax has named Ben Machielse as Executive Vice President, CMC, with responsibility for overseeing manufacturing, process technology, quality and regulatory functions. He was most recently Chief Executive Officer of rare disease company Vtesse, before its acquisition by Sucampo Pharmaceuticals, now a part of Mallinckrodt.

Biologics CDMO Avid Bioservices has appointed Nicholas Green president and chief executive officer, as well as a member of the company’s board of directors, effective July 30, 2020. He will succeed Rick Hancock who has served as interim president and CEO since May 2019. Mr. Hancock will continue to serve on Avid’s board of directors. Mr. Green has more than 30 years of experience in the global pharmaceutical and healthcare services industry with expertise in the contract manufacturing of novel pharmaceutical products.

Inovio has expanded its senior management team by appointing two experienced executives to lead its growth in the Asia market and to advance the clinical development of its DNA vaccine INO-4800 to combat the COVID-19 pandemic. Gene Kim joins as President of Inovio Asia, a wholly-owned subsidiary of Inovio based in Seoul, Korea and will report to Dr. J. Joseph Kim, Inovio CEO. Mammen (Anza) Mammen joins as Senior Vice President, Clinical Development, overseeing the clinical development of INO-4800. Dr. Mammen will report to Inovio CSO Dr. Laurent Humeau.

Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13. He joins from Boston Scientific, where he served the past nine years as Executive Vice President and Global President of its largest division, Interventional Cardiology. Mr. Ballinger will assume day-to-day operational leadership of Aldevron, facilitating the company’s rapid growth. Meanwhile, Aldevron’s co-founder, Michael Chambers, has been named Executive Chairman of the board. Mr. Chambers initiated the transition to allow him to focus on innovation, corporate strategy and working with clients and industry thought leaders to develop new technologies that enable genetic medicine.

Cambrex has named Tom Loewald as Chief Executive Officer and a member of the company’s board of directors, effective September 7th. As previously announced, in the interim, the company will be led by an Office of the CEO comprised of Wayne Hewett, Chairman of the Board, Robert Green, Executive Vice President and Chief Financial Officer, and Samantha Hanley, Senior Vice President and General Counsel. Mr. Loewald is a 15-year veteran of Thermo Fisher Scientific and currently serves as President of the Flexibles Division of flexible packaging manufacturer ProAmpac.

Moderna has hired Ray Jordan as Chief Corporate Affairs Officer, effective Monday, June 15. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer Stéphane Bancel. Mr. Jordan served as Senior Vice President, Corporate Affairs at Amgen from 2012 through 2019.


Boehringer Ingelheim has appointed Jean-Michel Boers (above) as US Country Managing Director, President and CEO. He will succeed Dr. Wolfgang Baiker, who will retire on July 31 after 31 years at the company. Mr Boers is currently President of Boehringer Ingelheim Pharmaceuticals, having joined in 1998 in Belgium, and advancing through various roles in corporate and operating units, including Corporate Vice President, Marketing and Sales Effectiveness, Country Managing Director for France and Human Pharma head of a European region consisting of mid-sized countries.


Lonza has announced that Pierre-Alain Ruffieux (above) has been appointed Chief Executive Officer effective 1 November, 2020. At that point, Albert Baehny will relinquish his position as CEO ad interim and return to his role as non-executive Chairman. Mr. Ruffieux is currently Head of Global Pharma Technical Operations at Roche. Prior to that he held roles of increasing seniority at Novartis and has over 20 years’ experience in biopharmaceuticals.


CDMO Alcami has named industry veteran Walter J. Kaczmarek III (above) as Chief Executive Officer. He has served in executive roles at sveral pharmaceutical companies, including as President of the Multisource Pharmaceuticals division of Mallinckrodt Pharmaceuticals, COO of Aceto Corporation, and most recently, as President and CEO of Cosette Pharmaceuticals. 

Vectura has appointed Trevor Archbold and Robert Gurley as Business Development Directors with responsibility for Europe and the US West Coast respectively. Additionally, Chris Vernall will join Vectura in August as Business Development Director, and will work alongside Mr Archbold in Europe. All three will report to Mark Bridgewater, who was appointed as Vectura’s Chief Commercial Officer in March 2020. Mr Archbold was most recently Strategic Account Manager at DuPont Pharma Solutions prior to stints at The Dow Chemical Company, Croda and Catalent. Mr Gurley has over 20 years’ CDMO experience, and joins from Cambrex where he was Director of Business Development for the North West territory. Mr Vernall joins Vectura from Nanopharm (part of Aptar Pharma), where he led its business development activities.

Steven Klosk will retire as Chief Executive Officer of Cambrex on June 30 after 28 years with the company. The company’s board is currently in the advanced stages of a search for Mr. Klosk’s successor. In the interim, the company will be led by an Office of the CEO comprised of Wayne Hewett, Chairman of the Board, Robert Green, Executive Vice President and Chief Financial Officer, and Samantha Hanley, Senior Vice President and General Counsel. In addition to Mr. Klosk’s retirement, Shawn Cavanagh will step down as President, Chief Operating Officer and member of the Board of Directors, but will take on the new role of strategic advisor to the incoming CEO and Board of Directors for an initial twelve-month period.

Catalent has appointed Charles Lickfold as Senior Vice President, Chief Information Officer. Mr. Lickfold succeeds John McGill, who, following a period of transition, plans to retire in September 2020. Mr. Lickfold will report to Alessandro Maselli, the company’s President and Chief Operating Officer, and assume responsibility for Catalent’s global IT services and technology. Prior to joining Catalent, he held numerous leadership positions, including Chief Information Officer at Alcami, Avara Pharmaceutical Services, and Gilbarco Veeder-Root.

Aruvant Palaniappan.jpg

Aruvant Sciences has announced the appointment of V. "Palani" Palaniappan (above) as Chief Technology Officer. In this role, Dr. Palaniappan will be charged with growing Aruvant's technical and manufacturing capabilities for current and future programs. With 25 years of research and drug development experience, including extensive work in chemistry, manufacturing and controls, Dr. Palaniappan will oversee the manufacturing of ARU-1801, a one-time, potentially curative investigational gene therapy for patients with sickle cell disease.

WuxiAppTec has appointed Dr. David Chang as Chief Executive Officer of its cell and gene therapy CDMO, WuXi Advanced Therapies. In this new executive role, Dr. Chang will provide strategic, scientific and operational leadership to the company's global cell and gene therapy R&D and manufacturing services. He was previously Corporate Vice President and Head of Cell Therapy Global Manufacturing at Celgene, where he oversaw the CAR-T manufacturing network and the global manufacturing sciences and technologies teams.

May 2020:

Immunomedics has announced that Harout Semerjian has decided to step down from his role as President and Chief Executive Officer. The biotech company says the decision, which is effective immediately, is "precipitated by the unfortunate significant logistical obstacles presented by the COVID-19 pandemic, including Mr. Semerjian’s ability to fully assume his duties as CEO." Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics, will continue to support the Company in an executive leadership role going forward.

Late-stage biopharmaceutical firm Elevar Therapeutics has announced Mark Gelder as Vice President of Medical Affairs. Dr. Gelder will build and lead Elevar's global medical organization. Dr. Gelder has 17 years of global medical affairs experience leading therapeutic oncology programs for Pfizer, Wyeth and Bayer, where he was involved in the approval and launch of several cancer therapeutics.

Biopharmaceutical company Hoth Therapeutics has appointed Michael H. Peters to its Scientific Advisory Board. Dr. Peters is the inventor of Hoth's newly licensed Novel Peptide COVID-19 Therapeutic, to prevent spike protein binding, which may be a leading cause of COVID-19.

James M. Loar has been appointed chief commercial officer at CJB Applied Technologies, where he will head up global commercial activities related to innovation, contract development and manufacturing. He previously worked at Cool Planet for five years, most recently as president and chief executive officer.

North Carolina-based CDMO Alcami has named Brian Dillion as Vice President of Regulatory Affairs and Quality Assurance and Jacquelyn Uribe as Vice President of Quality Operations. “Jacque and Brian bring broad compliance expertise with a track record of success upholding the rigorous standards required by both customers and regulators in high growth environments,” commented Chief Financial Officer Eric Evans.

Clinical-stage drug discovery, development and manufacturing company Sutro Biopharma has appointed Craig Berman as Vice President of Clinical Development promoted Regina Cheng to Vice President of Finance and Controller. Dr. Berman has over 17 years of experience in drug development, including immuno-oncology, and most recently was Vice President of Clinical Development at QED Therapeutics.

Selexis SA has promoted Myriam Adam to Vice President, Operations and Intellectual Property; Séverine Fagète to Vice President, Cell Line Development Services; and Valérie Le Fourn to Vice President, Research.

CordenPharma has appointed William Cashin as Chief Quality & Compliance Officer and Dr. Lee Newton as Chief Operating Officer. Both were previously at Lonza, where Mr Cashin served as Global Head Quality, Mammalian & Microbial and where Dr. Newton most recently held the role of Senior Vice President and Business Unit Head for Lonza’s small molecule API business.

Do you have a pharmaceutical people move that you'd like to share? Please contact gareth.carpenter@informa.com



Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.